Skip to main content

Table 3 Results of deterministic sensitivity analysis

From: Cost-effectiveness analysis of Vaborem in Carbapenem-resistant Enterobacterales (CRE) -Klebsiella pneumoniae infections in Italy

Input Δ Costs
(€)
Δ LY Δ QALY ICER
(€/LY)
ICUR
(€/QALY)
Base case scenario 3549 0.475 0.384 7473 9246
Model settings
 Discount rate 0% 3733 0.494 0.399 7551 9347
 Discount rate 5% 3436 0.463 0.374 7423 9181
 Time horizon 28 days − 666,50 0.000 0.002 Dominant Dominant
 Time horizon 1 year 717 0.164 0.135 4384 5316
 Alternative patients’ demographic characteristics* 3247 0.433 0.350 7491 9269
 Utility Values + 20% 3549 0.475 0.457 7473 7758
 Utility Values −20% 3549 0.475 0.307 7473 11,558
Calibration of effectiveness
 Long-term care (50%) 9499 0.475 0.356 20,004 26,691
 Mortality after 28 days + 20% 3025 0.423 0.342 7154 8833
 Mortality after 28 days −20% 4150 0.535 0.431 7762 9622
Calibration of costs
 Hospitalisation costs € 4981.23 2878 0.475 0.384 6061 7500
 RRT costs + 20% 3697 0.475 0.384 7786 9634
 RRT costs −20% 3400 0.475 0.384 7160 8859
 Vials sharing 3784 0.475 0.384 7968 9859
 Follow-up costs after home discharge € 87.41 3560 0.475 0.384 7497 9276
  1. *Patients with an average age of 68.0 years and predominantly male (63.1%) [34]
  2. BAT: best available therapy; ICER: incremental cost-effectiveness ratio; ICUR: incremental cost-utility ratio; LY: life years; QALY: quality assisted life years; RRT: renal replacement therapy